ALT-711 – (393121-34-1)

Alagebrium, formerly known as ALT-711, is a drug candidate developed by Alteon, Inc. It was the first clinically tested compound designed to break crosslinks caused by advanced glycation end products (AGEs), which contribute to aging and cardiovascular diseases.

AGEs are proteins that become glycated due to exposure to sugars, leading to tissue stiffening and degradation. Alagebrium has shown efficacy in reducing systolic blood pressure and providing therapeutic benefits for patients with diastolic heart failure. It targets the biochemical pathway leading to AGE formation, potentially reversing vascular stiffness and improving cardiovascular health.

Despite promising preclinical and clinical results, development of Alagebrium was discontinued in 2009 as the company shifted focus to other candidates.

The above informationis displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/Alagebrium
https://pubchem.ncbi.nlm.nih.gov/compound/216305#section=Molecular-Formula
https://www.nature.com/articles/hr201498
https://pmc.ncbi.nlm.nih.gov/articles/PMC5665628/